Linked Life Data

8481509

Source:http://linkedlifedata.com/resource/pubmed/id/8481509

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1993-6-1
pubmed:abstractText
Anti-B-blocked ricin (anti-B4-bR) combines the specificity of the anti-B4 (CD19) monoclonal antibody with the protein toxin "blocked ricin." In blocked ricin, affinity ligands are attached to the ricin B-chain to attenuate its lectin binding capacity. In a phase I trial, Anti-B4-bR was administered by 7-day continuous infusion to 12 patients in complete remission after autologous bone marrow transplantation (ABMT) for relapsed B-cell non-Hodgkin's lymphoma (NHL). Patients were treated at 20, 40, and 50 micrograms/kg/d for 7 days. Potentially therapeutic serum levels could be sustained for 3 to 4 days. The maximum tolerated dose was 40 micrograms/kg/d for 7 days (total 280 micrograms/kg). The dose-limiting toxicities were reversible grade IV thrombocytopenia and elevation of hepatic transaminases. Mild capillary leak syndrome was manifested by hypoalbuminemia, peripheral edema (4 patients), and dyspnea (1 patient). Anti-immunotoxin antibodies developed in 7 patients. Eleven patients remain in complete remission between 13 and 26 months post-ABMT (median 17 months). These results show that Anti-B4-bR can be administered with tolerable, reversible toxicities to patients with B-cell NHL in complete remission following ABMT.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
81
pubmed:geneSymbol
bcl-2
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
2263-71
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:8481509-Antibodies, Anti-Idiotypic, pubmed-meshheading:8481509-Antibodies, Monoclonal, pubmed-meshheading:8481509-Bone Marrow Transplantation, pubmed-meshheading:8481509-Combined Modality Therapy, pubmed-meshheading:8481509-DNA, Neoplasm, pubmed-meshheading:8481509-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:8481509-Follow-Up Studies, pubmed-meshheading:8481509-Humans, pubmed-meshheading:8481509-Immunotoxins, pubmed-meshheading:8481509-Lymphoma, B-Cell, pubmed-meshheading:8481509-Polymerase Chain Reaction, pubmed-meshheading:8481509-Protein-Tyrosine Kinases, pubmed-meshheading:8481509-Proto-Oncogene Proteins, pubmed-meshheading:8481509-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:8481509-Proto-Oncogenes, pubmed-meshheading:8481509-Ricin, pubmed-meshheading:8481509-Transplantation, Autologous
pubmed:year
1993
pubmed:articleTitle
Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
pubmed:affiliation
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase I